The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human study of FLX925, an orally administered FLT3/CDK4/CDK6 inhibitor, in subjects with relapsed or refractory acute myeloid leukemia (AML).
 
Naval Guastad Daver
No Relationships to Disclose
 
Marina Konopleva
No Relationships to Disclose
 
Holbrook Edwin Kohrt
No Relationships to Disclose
 
Jordan Scott Fridman
Employment - Flexus Biosciences; Gilead Sciences (I); Incyte; Incyte (I)
Leadership - Flexus Biosciences
Stock and Other Ownership Interests - Flexus Biosciences; Incyte; Incyte (I)
Patents, Royalties, Other Intellectual Property - Incyte
 
Dan Johnson
Employment - Flexus Biosciences
Stock and Other Ownership Interests - Flexus Biosciences
 
Juan C. Jaen
Employment - Flexus Biosciences
Leadership - Flexus Biosciences
Stock and Other Ownership Interests - Flexus Biosciences
Patents, Royalties, Other Intellectual Property - Flexus Biosciences
 
Hagop M. Kantarjian
Research Funding - Amgen (Inst); ARIAD (Inst); Bristol-Myers Squibb (Inst); Delta-Fly Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Jorge E. Cortes
No Relationships to Disclose